The Royalty Pharma dividend for the fourth quarter of 2026 will be $0.235 per Class A ordinary share, following board approval announced on October 16, 2026. Payment is scheduled for December 10, 2026, to shareholders of record at the close of business on November 13.
Key Takeaways
- The board approved a fourth-quarter distribution of $0.235 per Class A ordinary share.
- The shareholder record date is November 13, with payment due December 10, 2026.
- The declaration covers the upcoming quarterly payment, not future distributions.
Table of Contents
- Royalty Pharma dividend eligibility and payment
- Biopharmaceutical royalties underpin the business
- Conclusion
Royalty Pharma dividend eligibility and payment
Royalty Pharma’s fourth-quarter dividend announcement confirms the approved distribution and its payment timetable. The November record date identifies the shareholders entitled to receive the payment; the cash is scheduled to be distributed in December.
For a holding of 100 eligible Class A ordinary shares, the declared dividend amounts to $23.50 before any applicable taxes. The announcement does not provide a prior-quarter dividend comparison, so it does not establish an increase or decrease in the payout.
The release specifies a record date but does not separately identify an ex-dividend date. Those dates should not be treated as interchangeable when determining whether a share purchase carries entitlement to the distribution.
| Item | Details |
|---|---|
| Stock listing | Nasdaq: RPRX |
| Commercial portfolio | Royalties on more than 35 commercial products |
| Development portfolio | 16 development-stage product candidates |
Biopharmaceutical royalties underpin the business
Royalty Pharma receives payments tied directly to sales of therapies covered by its royalty portfolio. Its holdings include royalties on Vertex’s Trikafta and Alyftrek, GSK’s Trelegy and Roche’s Evrysdi.
The company funds drug development both by acquiring existing royalties from innovators and by partnering with companies to co-fund late-stage clinical trials and product launches in exchange for future royalties. That business model distinguishes its revenue interests from direct ownership of the pharmaceutical companies selling those treatments.
Conclusion
The next confirmed milestone is the November 13, 2026, shareholder record date, followed by the scheduled December 10 payment.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
